EQRx, Inc. (EQRX)
For informational purposes only. Not financial advice. Analysis by Sedat ANAK, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
EQRx, Inc. (EQRX) trades at $2.34. EQRx, Inc. is a pharmaceutical company focused on developing and commercializing innovative medicines for oncology and immune-inflammatory diseases. Market cap: $1.14B, Sector: Healthcare.
Price live · AI analysis from Mar 17, 2026Analyst Coverage for EQRX: EQRX does not currently have published analyst price targets in our coverage universe. This is common for smaller-cap names with limited Wall Street coverage. In the absence of analyst consensus, our AI model evaluates EQRX against Healthcare peers across nine fundamental dimensions and assigns an underweight signal based on the underlying data.
EQRX: 1/1 perspectives are bearish.
How is this calculated? →EQRx, Inc. (EQRX) Healthcare & Pipeline Overview
EQRx, Inc. is a biotechnology company dedicated to developing and commercializing innovative oncology and immune-inflammatory disease treatments. With a focus on affordability and accessibility, EQRx challenges traditional pharmaceutical pricing models, aiming to deliver high-quality medicines at sustainable costs within the competitive healthcare landscape.
What Is the Investment Thesis for EQRX?
EQRx presents a compelling investment thesis based on its disruptive approach to pharmaceutical pricing and its focus on developing treatments for high-demand therapeutic areas. The company's pipeline, featuring Aumolertinib and Sugemalimab in Phase III trials, represents significant near-term value drivers. With a market capitalization of $1.14B and a P/E ratio of 5.4, EQRx may be undervalued relative to its growth potential. Key catalysts include successful clinical trial outcomes and regulatory approvals for its lead drug candidates. However, the company faces risks associated with clinical trial failures, regulatory hurdles, and competition from established pharmaceutical companies. EQRx's commitment to affordability could reshape the pharmaceutical industry, offering long-term value for investors.
Based on FMP financials and quantitative analysis
EQRX Key Highlights
- Market Cap of $1.14B indicates substantial investor interest in EQRx's potential.
- P/E Ratio of 5.4 suggests the company may be undervalued compared to its earnings.
- Beta of 0.63 indicates lower volatility than the market average, potentially appealing to risk-averse investors.
- Focus on oncology and immune-inflammatory diseases addresses large and growing markets with unmet needs.
- Late-stage clinical programs (Phase III) for Aumolertinib and Sugemalimab provide near-term catalysts for potential revenue generation.
Who Are EQRX's Competitors?
EQRX is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.
| Company | Price | Change | Market Cap | AI Score |
|---|---|---|---|---|
| ALBO Albireo Pharma, Inc. | $44.15 | +0.00% | $915.89M | 71 |
| CBIO Crescent Biopharma, Inc. | $17.05 | -0.21% | $470.24M | — |
| CINC CinCor Pharma, Inc. | $29.06 | +0.00% | $1.27B | 47 |
| CTIC CTI BioPharma Corp. | $9.10 | +0.06% | $1.20B | 56 |
| ETHZ ETHZ | $3.53 | +0.00% | $56.39M | 52 |
| SNDX Syndax Pharmaceuticals, Inc. | $22.11 | +1.33% | $1.96B | 79 |
| ANAB AnaptysBio, Inc. | $63.69 | +0.43% | $2.75B | 79 |
| ABVX Abivax S.A. | $145.38 | +0.51% | $9.53B | 76 |
AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance
What Are EQRX's Key Strengths?
- Innovative approach to pharmaceutical pricing.
- Strong pipeline of drug candidates in oncology and immune-inflammatory diseases.
- Experienced management team.
- Strategic partnerships and collaborations.
What Are EQRX's Weaknesses?
- Reliance on successful clinical trial outcomes and regulatory approvals.
- Limited commercialization experience compared to established pharmaceutical companies.
- Potential for competition from biosimilars and generic drugs.
- Dependence on external funding for research and development.
What Could Drive EQRX Stock Higher?
- Release of Phase III clinical trial data for Aumolertinib in EGFR-mutated NSCLC (expected Q4 2026).
- Regulatory submission for Aumolertinib in the United States and Europe (expected H1 2027).
- Initiation of Phase III clinical trials for EQ176 in primary liver cancer (expected Q2 2027).
- Enrollment and progression of patients in Phase II clinical trials for Lerociclib in metastatic breast cancer.
- Expansion of strategic partnerships and collaborations to enhance pipeline and market reach.
What Are the Key Risks for EQRX?
- Weak fundamentals — a Piotroski F-Score of 1/9 flags soft profitability, leverage or efficiency.
- Insider selling — insiders were net sellers of roughly $103.4M recently.
- Clinical trial failures or delays could negatively impact the company's pipeline and valuation.
- Regulatory hurdles and rejection of drug submissions could delay or prevent market access.
- Competition from established pharmaceutical companies with greater resources and market share.
- Dependence on external funding for research and development.
- Uncertainty surrounding healthcare policies and reimbursement models.
What Are the Growth Opportunities for EQRX?
- Growth opportunity 1: Successful commercialization of Aumolertinib for EGFR-mutated NSCLC represents a significant growth opportunity. The NSCLC market is projected to reach $35.7 billion by 2027. Positive Phase III trial results and regulatory approval could drive rapid adoption of Aumolertinib, especially if EQRx can offer it at a more affordable price than existing EGFR inhibitors. The timeline for potential market entry is estimated within the next 1-2 years, pending regulatory decisions.
- Growth opportunity 2: Expansion of Sugemalimab's indications beyond Stage III and Stage IV NSCLC offers another avenue for growth. The global market for PD-L1 inhibitors is expected to reach $40 billion by 2028. Exploring Sugemalimab's efficacy in other cancer types could significantly broaden its market potential and extend its lifecycle. Clinical trials targeting new indications could commence within the next 2-3 years.
- Growth opportunity 3: Advancing Lerociclib through Phase II clinical trials for metastatic breast cancer could unlock a substantial market opportunity. The breast cancer therapeutics market is projected to reach $30 billion by 2025. Positive clinical data and subsequent regulatory approval could position Lerociclib as a valuable treatment option, particularly if EQRx can demonstrate superior efficacy or tolerability compared to existing CDK4/6 inhibitors. Phase II results are anticipated within the next 18-24 months.
- Growth opportunity 4: Developing and commercializing EQ176, an anti-programmed death-1 antibody for primary liver cancer, represents a strategic expansion into a high-need area. The liver cancer therapeutics market is expected to grow to $5 billion by 2027. Successful Phase III trials and regulatory approval could establish EQ176 as a key player in the liver cancer treatment landscape. The timeline for potential market entry is estimated within the next 3-4 years.
- Growth opportunity 5: Expanding the pipeline through strategic partnerships and acquisitions offers a long-term growth opportunity. By in-licensing or acquiring promising drug candidates in oncology and immune-inflammatory diseases, EQRx can diversify its portfolio and reduce its reliance on its existing pipeline. This strategy could involve collaborations with academic institutions, biotech companies, or pharmaceutical firms. The timeline for potential partnerships and acquisitions is ongoing.
What Opportunities Does EQRX Have?
- Expansion into new therapeutic areas and geographic markets.
- Acquisition of promising drug candidates and technologies.
- Development of novel drug delivery systems.
- Increased adoption of value-based pricing models.
What Threats Does EQRX Face?
- Clinical trial failures and regulatory setbacks.
- Competition from established pharmaceutical companies with greater resources.
- Changes in healthcare policies and reimbursement models.
- Economic downturns and market volatility.
What Are EQRX's Competitive Advantages?
- Focus on affordability creates a competitive advantage by increasing market access.
- Pipeline of innovative drug candidates in high-demand therapeutic areas.
- Strategic partnerships and collaborations enhance research and development capabilities.
- Experienced management team with a track record of success in the pharmaceutical industry.
What Does EQRX Do?
EQRx, Inc. was founded in 2019 with the mission of creating and delivering innovative medicines to patients at radically lower prices. Recognizing the financial burden that many patients face when accessing life-saving treatments, EQRx set out to disrupt the traditional pharmaceutical business model. The company is headquartered in Cambridge, Massachusetts, and is focused on developing therapies for oncology and immune-inflammatory diseases. EQRx's pipeline includes pre-registrational programs such as Aumolertinib, an epidermal growth factor receptor (EGFR) inhibitor for non-small cell lung cancer (NSCLC), and Sugemalimab, an anti-programmed death-ligand 1 antibody also for NSCLC. Other programs include Lerociclib, a cyclin-dependent kinase 4/6 inhibitor for metastatic breast cancer; EQ176, an anti-programmed death-1 antibody for primary liver cancer; and EQ121, a selective janus kinase-1 inhibitor in Phase I trials. By focusing on clinically validated targets and leveraging efficient drug development strategies, EQRx aims to bring high-quality, affordable medicines to market more quickly and efficiently. The company’s approach involves strategic partnerships and collaborations to enhance its research and development capabilities and expand its global reach.
What Products and Services Does EQRX Offer?
- Develop innovative medicines for oncology and immune-inflammatory diseases.
- Conduct clinical trials to evaluate the safety and efficacy of drug candidates.
- Seek regulatory approvals from health authorities like the FDA.
- Manufacture and commercialize approved medicines.
- Establish partnerships and collaborations to expand research and development capabilities.
- Challenge traditional pharmaceutical pricing models by offering affordable treatments.
- Focus on clinically validated targets to improve drug development efficiency.
How Does EQRX Make Money?
- Develop and commercialize pharmaceutical products.
- Generate revenue through sales of approved medicines.
- Partner with other companies to share development costs and risks.
- Focus on affordability to increase market access and adoption.
What Industry Does EQRX Operate In?
EQRx operates within the biotechnology industry, a sector characterized by high innovation and significant investment in research and development. The market for oncology and immune-inflammatory disease treatments is substantial and growing, driven by aging populations and increasing prevalence of chronic diseases. EQRx differentiates itself through its focus on affordability, challenging the traditional pricing models of established pharmaceutical companies. Competitors include companies like ALBO, CBIO, CINC, CTIC, and ETHZ, which are also developing therapies in similar therapeutic areas. The success of EQRx will depend on its ability to navigate the complex regulatory landscape, secure partnerships, and successfully commercialize its pipeline products.
Who Are EQRX's Key Customers?
- Patients with cancer and immune-inflammatory diseases.
- Healthcare providers who prescribe and administer medications.
- Hospitals and clinics that purchase medications.
- Pharmacy benefit managers (PBMs) and insurance companies that reimburse for medications.
Company Profile
EQRx, Inc. operates in the Biotechnology industry within the Healthcare sector. It is headquartered in Cambridge, US. The company is led by CEO Melanie I. Nallicheri. EQRX has traded publicly since 2021.
F-Score 1/9Financial Health
EQRx, Inc.'s Piotroski F-Score is 1/9, a 9-point checklist of profitability, leverage and efficiency — flagging fundamental weakness worth scrutiny. Its Altman Z-Score of 9.77 places it in the safe zone, indicating low near-term bankruptcy risk.
ROE 14%Key Financial Metrics
Return on equity for EQRx, Inc. stands at 14.2%, a gauge of how efficiently it converts shareholder capital into profit. Return on assets is 14.1%, showing how much profit it generates from its asset base. EQRX trades at a trailing price-to-earnings ratio of 5.40, below the Healthcare sector average of ~23x. Its free cash flow yield is -25.3%, a gauge of the cash the business throws off relative to its market value. A current ratio of 27.51 indicates the company holds enough short-term assets to cover its near-term obligations. Its earnings yield is 18.5%, the inverse of the P/E and a quick read on earnings relative to price.
EQRX Valuation & Market Position
With a $1.14B market cap, EQRx, Inc. sits in the small-cap segment of the market.
Net sellingInsider Activity
The most recent 12 insider filings for EQRx, Inc. break down as 11 sales and 1 purchases. On net that is roughly 22.2M shares disposed (about $103.4M), a signal worth weighing alongside the fundamentals.
EQRX Financials
Fundamental Snapshot
Based on FMP financials and quantitative analysis
Bull Case vs Bear Case
Bull Case
- Recent insider buying suggests confidence in EQRx's future, indicating that leadership believes in the company's potential.
- Community sentiment has shifted positively, with discussions highlighting the innovative drug pipeline that could disrupt existing markets.
- Analysts are increasingly recognizing EQRx's unique approach to pricing and access, which resonates well with healthcare reform trends.
- Partnerships with established pharmaceutical companies have strengthened EQRx's credibility, enhancing market perception.
Bear Case
- Concerns about the competitive landscape persist, as traditional pharma companies ramp up their own pricing strategies, potentially overshadowing EQRx's offerings.
- Social sentiment reflects skepticism about the timeline for product approvals, with some community members questioning the feasibility of their ambitious goals.
- Recent regulatory challenges have raised doubts about EQRx's ability to navigate the complex landscape, impacting investor confidence.
- Market perception remains cautious, with some analysts pointing to the high level of uncertainty surrounding the commercialization of new drugs.
AI-generated arguments based on insider flow, news sentiment and technicals — not financial advice · April 2026
EQRX Latest News
No recent news available for EQRX.
EQRX Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations from Benzinga, Yahoo Finance, and Finnhub for EQRX.
Price Targets
Wall Street price target analysis for EQRX.
EQRX MoonshotScore
What does this score mean?
The MoonshotScore rates EQRX's growth potential on a scale of 0-100 across multiple factors including innovation, market disruption, financial health, and momentum.
Leadership: Melanie I. Nallicheri
CEO
Melanie I. Nallicheri brings extensive experience in the pharmaceutical and biotechnology industries to her role as CEO of EQRx. Prior to joining EQRx, she held leadership positions at several prominent healthcare companies, where she focused on strategic planning, business development, and commercial operations. Her background includes a strong foundation in finance and a proven track record of driving growth and innovation in the healthcare sector. She is known for her strategic vision and commitment to improving patient access to affordable medicines.
Track Record: Under Melanie I. Nallicheri's leadership, EQRx has made significant strides in advancing its pipeline and establishing its presence in the pharmaceutical market. She has overseen the progression of key drug candidates through clinical trials and has forged strategic partnerships to expand the company's research and development capabilities. Her focus on affordability has positioned EQRx as a disruptor in the industry, challenging traditional pricing models and advocating for greater patient access to life-saving treatments.
Common Questions About EQRX (Healthcare)
What does EQRx, Inc. do?
EQRx, Inc. is a pharmaceutical company focused on developing and commercializing innovative medicines for oncology and immune-inflammatory diseases. The company's primary mission is to provide affordable access to novel therapies, challenging the traditional pricing models prevalent in the pharmaceutical industry. EQRx aims to deliver high-quality medicines at sustainable costs, addressing unmet needs in the treatment of cancer and immune-related disorders. Its pipeline includes several drug candidates in various stages of clinical development, targeting clinically validated pathways.
What do analysts say about EQRX stock?
Analyst coverage of EQRX is currently developing, with initial assessments focusing on the company's disruptive business model and promising pipeline. Key valuation metrics under consideration include the potential market size for its lead drug candidates, the likelihood of successful clinical trial outcomes, and the competitive landscape. Growth considerations center on EQRx's ability to secure regulatory approvals, establish commercial partnerships, and maintain its cost-effective pricing strategy. Analyst consensus is still forming, but the company's innovative approach and focus on affordability are generally viewed positively.
What are the main risks for EQRX?
EQRx faces several risks inherent in the pharmaceutical industry, including the potential for clinical trial failures, regulatory setbacks, and competition from established players. The success of its pipeline depends on positive clinical data and favorable regulatory decisions, which are subject to uncertainty. Furthermore, EQRx's focus on affordability may impact its profitability and ability to compete with companies that have greater financial resources. Changes in healthcare policies and reimbursement models could also affect the company's market access and revenue potential. Managing these risks will be critical to EQRx's long-term success.
What is EQRx, Inc.'s drug pipeline status?
EQRx, Inc.'s drug pipeline includes several promising candidates in various stages of clinical development. Aumolertinib, an EGFR inhibitor for NSCLC, and Sugemalimab, an anti-PD-L1 antibody also for NSCLC, are in Phase III clinical trials, representing near-term potential catalysts. Lerociclib, a CDK4/6 inhibitor for metastatic breast cancer, is in Phase II trials. EQ176, an anti-PD-1 antibody for primary liver cancer, is in Phase III trials, and EQ121, a selective JAK1 inhibitor, is in Phase I trials. The company's focus is on oncology and immune-inflammatory diseases, with the goal of bringing affordable and effective treatments to market.
What are the key growth opportunities for EQRX in healthcare?
EQRx, Inc. has several key growth opportunities within the healthcare sector. These include expanding the indications for its existing drug candidates, such as Sugemalimab, into other cancer types. Another opportunity lies in geographic expansion, particularly into emerging markets where affordable medicines are in high demand. EQRx can also pursue strategic partnerships and acquisitions to broaden its pipeline and access new technologies. Furthermore, the company can leverage its focus on affordability to gain market share and disrupt the traditional pharmaceutical pricing model, driving long-term growth and value creation.
What are the key factors to evaluate for EQRX?
Evaluate EQRX on fundamentals, analyst consensus, and risk factors. P/E: 5.4x vs the S&P 500's ~20-25x. Not financial advice.
How frequently does EQRX data refresh on this page?
EQRX prices update in real time during U.S. market hours. Fundamentals refresh after quarterly filings; analyst ratings and AI insights update daily; news is aggregated continuously.
What has driven EQRX's recent stock price performance?
EQRx, Inc. (EQRX) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: Innovative approach to pharmaceutical pricing. See the News tab for the latest drivers. Past performance does not predict future results.
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.
- Information is based on publicly available sources and may be subject to change.
- AI analysis is pending and may provide additional insights.